We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Plasma HSP90α Levels Used for Detection of Hepatocellular Carcinoma

By LabMedica International staff writers
Posted on 14 Jan 2020
Liver cancer is composed mostly of primary liver cancers and secondary liver cancers. More...
Hepatocellular carcinoma (HCC), as the major type of primary liver cancer, is the fifth most common tumor worldwide and the third leading cause of cancer mortality, responsible for 745,500 cancer deaths annually.

HCC screening is based on measurement of serum alpha-fetoprotein (AFP) as well as imaging technologies and histology. Heat shock protein 90 (HSP90) is an evolutionarily highly conserved intracellular molecular chaperone that is usually induced in response to cellular stress and therefore HSP90 is a potential biomarker for tumor diagnosis and prognosis.

Scientists at the Guangxi Medical University (Nanning, China) enrolled from January 1, 2018 to February 28, 2019, a total of 801 liver disease patients in the Hepatobiliary Surgery Department of the Affiliated Tumor Hospital of Guangxi Medical University. The subjects included were 659 HCC patients, 114 secondary hepatic carcinoma (SHC) patients and 28 patients with hepatic hemangioma (HH).

The levels of plasma HSP90α were measured by using the enzyme-linked immunosorbent assay (ELISA) kit for HSP90α protein (Yantai Protgen Biotechnology Development Co. Ltd, Yantai, China). The optical density was measured by using a spectrophotometer at 450 nm for the detection wavelength with 620 nm as the reference wavelength. The levels of serum AFP were measured using Cobas electro-chemiluminescence immunoassay kits (Roche Diagnostics, Mannheim, Germany).

The medical team reported that the levels of plasma HSP90α in HCC patients were significantly higher (144.08 ± 4.98 ng/mL) than in healthy donors (46.81 ± 1.11 ng/mL) and in patients with hepatic hemangioma (61.56 ± 8.20 ng/mL) or SHC (111.96 ± 10.08 ng/mL). The levels were associated with age, Barcelona Clinical Liver Cancer (BCLC) stage, levels of AFP, tumor size, tumor number, portal vein tumor thrombus (PVTT), extrahepatic metastasis (EHM), and Child-Pugh stage in the HCC cohort. In addition, the levels of plasma HSP90α showed an upward trend along with the progression of the BCLC stage. The combination of HSP90α and AFP significantly improved the diagnostic efficiency for HCC patients.

The authors concluded that the levels of plasma HSP90α in healthy donors, benign liver tumor cohort, SHC cohort and HCC cohort showed a statistically significant increasing trend in this study. The combination of HSP90α and AFP significantly improved the diagnostic efficiency for HCC patients and these simple tests can be useful in both rural and cosmopolitan settings. The study was published on January 2, 2020 in the journal BMC Cancer.

Related Links:
Guangxi Medical University
Yantai Protgen Biotechnology Development Co. Ltd
Roche Diagnostics



Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.